[ad_1]
IRVINE, Calif., March 05, 2024 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), whose mission is to focus on unmet needs and apply proven science and new technologies To revolutionize patient care, starting with ophthalmology, today it was announced that Tarsus will be participating in the following conferences:
All dates and times listed above are subject to change. Please check the Tarsus website for the latest information. A live webcast of the fireside chat will be available on the Events section of the Tarsus website. Replays will be available for 48 hours and will be archived for a limited time.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. applies proven science and new technologies to revolutionize patient care, starting with eye care. Tarsus is advancing its product pipeline to address multiple conditions with unmet need across a range of therapeutic categories including eye care, dermatology and infectious disease prevention. XDEMVY (lotilaner eye drops) 0.25% has been approved by the FDA for treatment in the United States Demodex Blepharitis. Tarsus is also developing TP-03 as an investigational therapy for the treatment of meibomian gland disease, TP-04 for the treatment of rosacea, and TP-05 as an oral tablet for the prevention of Lyme disease, all of which are in Phase 2.
contact method:
Media contact information:
Adrienne Camp
Senior Director of Corporate Communications
(949) 922-0801
AKemp@tarsusrx.com
Investor contact information:
David Nakasone
Investor Relations Manager
(949)620-3223
DNakasone@tarsusrx.com
[ad_2]
Source link